Novartis hopes Kisqali data will help narrow gap to blockbuster rival
Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance.
from Reuters: Health News https://reut.rs/319EjT4
http://bit.ly/2zwRqiM